Enanta Pharmaceuticals Inc

-0.36 (-0.86%)
5:00:00 PM EDT: $42.09 +0.36 (+0.86%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)871.55M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$19.17 Million
Adjusted EPS-$1.96
See more estimates
10-Day MA$43.93
50-Day MA$49.10
200-Day MA$50.34
See more pivots

Enanta Pharmaceuticals Inc Stock, NASDAQ:ENTA

500 Arsenal Street, Watertown, Massachusetts 02472
United States of America
Phone: +1.617.607.0800
Number of Employees: 160


Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.